GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) today announced that they have entered a new research ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market ...

(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...

This European review of the prefilled syringe follows GSK's receipt of approval from the US Food & Drug Administration on January 8. GSK is also investigating submission of the new presentation to ...